When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
CRL - Charles River Laboratories: Weak Biopharma Spending Is Transitory; Initiate With 'Hold'
Charles River Laboratories International Inc.
2024-02-16 09:06:59 ET
Summary
Charles River Laboratories achieved only 6.5% organic revenue growth in FY23 due to weakness in the broader life science industry.
CRL offers a comprehensive range of services to pharmaceutical and biopharmaceutical companies, with a broad customer base and a significant market share.
CRL's growth drivers include discovery and safety assessment services, the research model industry, and the forecasted growth in the global CRO market.